<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01817725</url>
  </required_header>
  <id_info>
    <org_study_id>ChangGungMH 101-3594A3</org_study_id>
    <nct_id>NCT01817725</nct_id>
  </id_info>
  <brief_title>Hepatitis B Vaccine in Chronic Hepatitis B Patients With Low Serum HBsAg</brief_title>
  <official_title>Effect of Hepatitis B Vaccine in Chronic Hepatitis B Patients With Low Serum HBsAg—a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      The HBsAg clearance rate in interferon-treated responders is significantly higher than that
      in lamivudine-treated responders, implying immune control is the key to HBsAg clearance.
      There is a good chance to further increase the cure rate if the investigators can enhance the
      HBV-specific immune response when the HBsAg level already comes to a low level.

      Hypothesis: HBsAg-based vaccine can enhance HBsAg clearance in chronic hepatitis B patients
      whose HBsAg already &lt;=2000 IU/ml.

      Patients and methods:

      This pilot study will enroll 20 chronic hepatitis B patients with HBsAg ≦2000 IU/ml, no
      hepatic decompensation, no HIV coinfection, nor clinical immunodeficiency. Engerix-B vaccine
      (20μg for &lt;20 years old and 40 μg for ≥ 20 years old) will be given every 2 months for one
      year. HBsAg quantification, anti-HBs, and HBV DNA will be surveyed regularly before each dose
      during the treatment period and every 3 months for another year following the last dose.
      Viral and cellular factors will be studied to discover determinants affecting HBsAg
      clearance.

      Aims

        1. To elucidate whether HBsAg-based vaccine can reactivate host immunity to eliminate
           chronic HBV infection in patients with low titer HBsAg.

        2. To delineate the doses to response (HBsAg clearance or decline rate) correlation so as
           to design a feasible schedule for future clinical trials in a larger group of patients.

        3. To discover viral and host factors which can be used as biomarkers for personalized
           vaccine therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vaccination schedule:

      Engerix-B (20μg/ml, GlaxoSmithKline Biologicals) will be administered intramuscularly at 0,
      2, 4, 6, 8, 10, 12 months or until HBsAg clearance. The dosage will be 20μg in those &lt;= 20
      years old and 40μg in those &gt; 20 years old.

      HBsAg and anti-HBs:

      qHBsAg will be checked by commercial kits (Elecsys, Roche Diagnostics, Indianapolis, IN) at
      baseline, right before every dose, and every 3 months following the last dose for one year.
      ALT, AST, Alpha-fetoprotein, bilirubin and anti-HBs will be checked simultaneously.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HBsAg Levels From Baseline to 2 Years</measure>
    <time_frame>2 years</time_frame>
    <description>The difference of HBsAg levels at the end of follow up (2 years) and baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-HBs Seropositivity</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Engerix-B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Engerix-B (20 μg/ml, GlaxoSmithKline) was administered at 0-2-4-6-8-10-12 months in dosage of 40μg for &gt;20 years old and 20μg for &lt; or =20 years old</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HBV vaccine (Engerix B)</intervention_name>
    <description>Engerix-B (20μg/ml, GlaxoSmithKline Biologicals) is administered intramuscularly at 0, 2, 4, 6, 8, 10, 12 months. The dosage will be 20μg in those &lt;= 20 years old and 40μg in those &gt; 20 years old.</description>
    <arm_group_label>Engerix-B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Naïve or treated chronic hepatitis B patients with positive HBsAg and negative HBeAg;

          2. Quantitative serum HBsAg (qHBsAg) &lt;2000 IU/ml;

          3. No HIV co-infection;

          4. No obvious immunodeficiency (such as renal failure, chemotherapy, radiotherapy,
             immunosuppressant);

          5. Aged 3 to 80 years;

        Exclusion Criteria:

          1. Pregnancy

          2. Allergic to HBV vaccine or yeast.

          3. Hepatic decompensation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming-Wei Lai</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chao-Wei Hsu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chau-Ting Yeh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan Xian</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2013</study_first_submitted>
  <study_first_submitted_qc>March 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2013</study_first_posted>
  <results_first_submitted>February 2, 2017</results_first_submitted>
  <results_first_submitted_qc>March 22, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 2, 2017</results_first_posted>
  <last_update_submitted>March 22, 2017</last_update_submitted>
  <last_update_submitted_qc>March 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chang Gung Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Ming-Wei Lai</investigator_full_name>
    <investigator_title>M.D., Ph.D.</investigator_title>
  </responsible_party>
  <keyword>Therapeutic vaccine</keyword>
  <keyword>HBsAg clearance</keyword>
  <keyword>Immune clearance</keyword>
  <keyword>HBsAg clearance induced by vaccination</keyword>
  <keyword>s seroconversion in carriers after vaccination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Engerix-B</title>
          <description>Engerix-B (20 μg/ml, GlaxoSmithKline) was administered at 0-2-4-6-8-10-12 months in dosage of 40μg for &gt;20 years old and 20μg for &lt; or =20 years old
HBV vaccine (Engerix B): Engerix-B (20μg/ml, GlaxoSmithKline Biologicals) is administered intramuscularly at 0, 2, 4, 6, 8, 10, 12 months. The dosage is 20μg in those &lt;= 20 years old and 40μg in those &gt; 20 years old.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Engerix-B</title>
          <description>Engerix-B (20 μg/ml, GlaxoSmithKline) was administered at 0-2-4-6-8-10-12 months in dosage of 40μg for &gt;20 years old and 20μg for &lt; or =20 years old
HBV vaccine (Engerix B): Engerix-B (20μg/ml, GlaxoSmithKline Biologicals) is administered intramuscularly at 0, 2, 4, 6, 8, 10, 12 months. The dosage will be 20μg in those &lt;= 20 years old and 40μg in those &gt; 20 years old.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.3" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in HBsAg Levels From Baseline to 2 Years</title>
        <description>The difference of HBsAg levels at the end of follow up (2 years) and baseline</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Engerix-B</title>
            <description>Engerix-B (20 μg/ml, GlaxoSmithKline) was administered at 0-2-4-6-8-10-12 months in dosage of 40μg for &gt;20 years old and 20μg for &lt; or =20 years old
HBV vaccine (Engerix B): Engerix-B (20μg/ml, GlaxoSmithKline Biologicals) is administered intramuscularly at 0, 2, 4, 6, 8, 10, 12 months. The dosage is 20μg in those &lt;= 20 years old and 40μg in those &gt; 20 years old.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HBsAg Levels From Baseline to 2 Years</title>
          <description>The difference of HBsAg levels at the end of follow up (2 years) and baseline</description>
          <units>log IU/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-HBs Seropositivity</title>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Engerix-B</title>
            <description>Engerix-B (20 μg/ml, GlaxoSmithKline) was administered at 0-2-4-6-8-10-12 months in dosage of 40μg for &gt;20 years old and 20μg for &lt; or =20 years old
HBV vaccine (Engerix B): Engerix-B (20μg/ml, GlaxoSmithKline Biologicals) is administered intramuscularly at 0, 2, 4, 6, 8, 10, 12 months. The dosage is 20μg in those &lt;= 20 years old and 40μg in those &gt; 20 years old.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-HBs Seropositivity</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Engerix-B</title>
          <description>Engerix-B (20 μg/ml, GlaxoSmithKline) was administered at 0-2-4-6-8-10-12 months in dosage of 40μg for &gt;20 years old and 20μg for &lt; or =20 years old
HBV vaccine (Engerix B): Engerix-B (20μg/ml, GlaxoSmithKline Biologicals) is administered intramuscularly at 0, 2, 4, 6, 8, 10, 12 months. The dosage is 20μg in those &lt;= 20 years old and 40μg in those &gt; 20 years old.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This is a pilot study. A control arm is not included. However, from literature review, natural HBsAg decay without seroconversion was around 0.054~0.058 log IU/ml/year.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Ming-Wei Lai</name_or_title>
      <organization>Chang Gung Memorial Hospital, Linkou Branch</organization>
      <phone>886-3-3281200 ext 8969</phone>
      <email>a22141@adm.cgmh.org.tw</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

